B
Bailard Portfolio holdings
AUM
$4.29B
1-Year Return
18.39%
This Quarter Return
-10.43%
1 Year Return
+18.39%
3 Year Return
+76.25%
5 Year Return
+133.74%
10 Year Return
+353.73%
AUM
$1.48B
AUM Growth
-$231M
(-14%)
Cap. Flow
-$11.6M
Cap. Flow
% of AUM
-0.78%
Top 10 Holdings %
Top 10 Hldgs %
29.59%
Holding
596
New
70
Increased
138
Reduced
203
Closed
108
Top Buys
| 1 |
iShares Short Treasury Bond ETF
SHV
|
+$56.7M |
| 2 |
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
|
+$56.6M |
| 3 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$37.1M |
| 4 |
iShares Gold Trust
IAU
|
+$29.2M |
| 5 |
iShares Core MSCI EAFE ETF
IEFA
|
+$22.2M |
Top Sells
| 1 |
Invesco QQQ Trust
QQQ
|
+$50.7M |
| 2 |
iShares Russell 2000 Value ETF
IWN
|
+$47.5M |
| 3 |
SPDR Gold Trust
GLD
|
+$35.8M |
| 4 |
SPDR S&P 500 ETF Trust
SPY
|
+$33.4M |
| 5 |
SPDR Nuveen ICE Short Term Municipal Bond ETF
SHM
|
+$5.64M |
Sector Composition
| 1 | Technology | 13.53% |
| 2 | Healthcare | 6.24% |
| 3 | Communication Services | 5.22% |
| 4 | Financials | 5% |
| 5 | Industrials | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Universal Corp
UVV
$1.38B
| $439K | 0.03% |
8,100
-800
| -9% | -$43.4K |
|
327
iShares Biotechnology ETF
IBB
$5.64B
| $437K | 0.03% |
4,529
-773
| -15% | -$74.6K |
|
328
Radian Group
RDN
$4.73B
| $437K | 0.03% |
26,700
| – | – |
|
329
Medpace
MEDP
$13.4B
| $434K | 0.03% |
8,200
-3,500
| -30% | -$185K |
|
|
VRS
330
DELISTED
Verso Corporation
VRS
| $432K | 0.03% |
19,300
-9,000
| -32% | -$201K |
|
331
Schwab US Mid-Cap ETF
SCHM
$12.2B
| $431K | 0.03% |
26,961
| – | – |
|
332
Enova International
ENVA
$2.89B
| $428K | 0.03% |
22,000
+9,200
| +72% | +$179K |
|
333
Hurco Companies Inc
HURC
$114M
| $428K | 0.03% |
11,992
-2,258
| -16% | -$80.6K |
|
334
BioMarin Pharmaceuticals
BMRN
$10.5B
| $426K | 0.03% |
5,000
| – | – |
|
335
Steel Dynamics
STLD
$19.5B
| $424K | 0.03% |
14,109
+3,844
| +37% | +$116K |
|
336
Independence Realty Trust
IRT
$4.07B
| $421K | 0.03% |
45,900
-4,300
| -9% | -$39.4K |
|
337
Kura Oncology
KURA
$710M
| $421K | 0.03% |
30,000
| – | – |
|
338
KBR
KBR
$6.42B
| $420K | 0.03% |
27,700
| – | – |
|
339
Steven Madden
SHOO
$2.22B
| $418K | 0.03% |
+13,800
| New | +$418K |
|
340
Esperion Therapeutics
ESPR
$524M
| $414K | 0.03% |
9,000
| – | – |
|
341
inTEST
INTT
$88.6M
| $413K | 0.03% |
67,340
-1,180
| -2% | -$7.24K |
|
342
Progress Software
PRGS
$1.83B
| $412K | 0.03% |
11,600
-5,100
| -31% | -$181K |
|
343
Rocky Brands
RCKY
$216M
| $411K | 0.03% |
15,796
-4,400
| -22% | -$114K |
|
344
Matsons
MATX
$3.28B
| $410K | 0.03% |
12,800
| – | – |
|
345
Independent Bank Corp
IBCP
$661M
| $408K | 0.03% |
19,400
-11,100
| -36% | -$233K |
|
346
National Healthcare
NHC
$1.75B
| $408K | 0.03% |
5,200
-3,600
| -41% | -$282K |
|
347
OFG Bancorp
OFG
$1.96B
| $408K | 0.03% |
+24,800
| New | +$408K |
|
348
INNOVATE Corp
VATE
$65.2M
| $408K | 0.03% |
+15,460
| New | +$408K |
|
349
Acco Brands
ACCO
$359M
| $405K | 0.03% |
59,800
+8,900
| +17% | +$60.3K |
|
350
Dana Inc
DAN
$2.73B
| $402K | 0.03% |
29,500
-148,428
| -83% | -$2.02M |
|